ClinicalTrials.gg
CompletedNCT05088642Updated Oct 22, 2021

A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects

A Phase 1 interventional study of Hetrombopag Olamine Tablet in Sever Aplastic Anaemia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-10-22.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Sep 2020, registered Oct 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Anemia, Aplastic with a site in China — 39 open to participants now, 43 under way, 1 of them phase 3. Anemia, Aplastic · China.

Enrollment
62nd of 74
24 · median 52
Started
2020
with 5 others
Phase 1
7 of 88
1 open now
Registered
32nd of 88
by date
Lead sponsor
7 of 88
Jiangsu HengRui Medicine Co., Ltd.

Among the 88 studies in Anemia, Aplastic with a site in China, this one is the 62nd largest by enrollment of the 74 interventional ones that give a count, is one of 6 that started in 2020, is one of 7 in phase 1, and was the 32nd registered.

Anemia, Aplastic

372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

39 of the 88 studies in Anemia, Aplastic with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Anemia, Aplastic with a site in China, or all of them as a file.
02

Study summary

This is a single-dose, open-label, phase I clinical study evaluating the PK of hetrombopag in subjects with mild hepatic impairment (Child-Pugh Class A), subjects with moderate hepatic impairment (Child-Pugh Class B), as well as age-, weight-, and gender-matched subjects with normal hepatic function.

03

Conditions studied

  • Sever Aplastic Anaemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the form before the study and fully understand the study content, process, and possible adverse reactions; able to complete the study as required by the clinical study protocol;
  2. Subjects (and their partners) are willing to adopt effective measures from screening to 6 months after the last study administration. See Appendix 1 for specific contraceptive measures;
  3. Aged 18-65 years (inclusive), male or female;
  4. (BMI = weight (kg)/height2 (m2)): 18-30 kg/m2 (inclusive);
  5. For subjects with normal hepatic function: normal or abnormal but not laboratory findings (hematology, blood biochemistry, urinalysis, and coagulation function);
  6. For subjects with normal hepatic function: no history of severe primary disorders involving major organs, including but not limited to the gastrointestinal, respiratory, renal, hepatic, neural, hematological, endocrine, neoplastic, immunological, psychiatric, or cardiovascular and cerebrovascular disorders.

    Subjects with hepatic insufficiency must also meet the following inclusion criteria:

  7. Have not received medication within 4 weeks before screening, or have received stable medication for at least 4 weeks for hepatic impairment and/or other concurrent diseases requiring long-term treatment;
  8. With Class A or B hepatic insufficiency caused by prior primary liver disorders (except drug-induced liver diseases).

Exclusion criteria

Exclusion Criteria:

  1. Average daily consumption of > 5 cigarettes within 3 months before screening;
  2. Allergic constitution, or allergy to any component of hetrombopag olamine tablets;
  3. Average daily alcohol consumption of > 15 g for females (e.g., 145 mL of wine, 497 mL of beer, or 43 mL of low-alcohol liquor) and > 25 g for males (e.g., 290 mL of wine, 994 mL of beer, or 86 mL of low-alcohol liquor) within 3 months before screening;
  4. History of drug abuse within 3 months before screening;
  5. Have donated or lost ≥ 400 mL of blood, or have received blood transfusion within 3 months before screening;
  6. Have undergone major surgery within 6 months before screening, or with incomplete healing of surgical incision;
  7. History of deep vein thrombosis or other thromboembolic events, or clinical symptoms suggesting thrombophilia;
  8. Have received TPO receptor agonists (such as eltrombopag and romiplostim) or TPO within 1 month before screening;
  9. Have taken Chinese herbal medicines or any drug that affects the PK of hetrombopag within 14 days before study administration (see Appendix 2 for drug-drug interaction evaluation);
  10. Hypertension [systolic blood pressure (SBP) ≥ 160 mmHg and/or diastolic blood pressure (DBP) ≥ 100 mmHg, confirmed by a re-measurement];
  11. Female subjects who are in lactation or have a positive serum pregnancy test result at screening or during the study;
  12. Abnormal and 12-lead results (such as tachycardia/bradycardia requiring pharmacological treatment, second- or third-degree atrioventricular block or interval prolongation (≥ 470 ms for males, ≥ 480 ms for females) (corrected according to Fridericia's formula), or other clinically significant abnormalities assessed by the clinician);
  13. Estimated (eGFR) \< 60 mL/min/1.73 m2 calculated using the Modification of Diet in Renal Disease (MDRD) equation;
  14. Have malignant tumors or history of malignant tumors within 5 years before screening (except treated non-melanoma skin cancer without sign of recurrence and resected cervical intraepithelial neoplasia);
  15. For subjects with normal hepatic function: have participated in any drug or medical device clinical trials within 3 months before screening; for subjects with hepatic insufficiency: have participated in any drug or medical device clinical trials within 1 month before screening;
  16. For subjects with normal hepatic function: test positive for surface antigen, antibody or hepatitis C core antigen, antibody, or syphilis antibody in screening;
  17. Probably undergo surgery or be hospitalized during the study;
  18. Have consumed alcohol (or positive for breath alcohol test), grapefruit/grapefruit juice, or any food or beverage containing methylxanthine (such as coffee, tea, cola, chocolate, and energy drink), have participated in strenuous physical activities, or have other factors that may affect drug absorption, distribution, metabolism, and excretion within 1 day before study administration;
  19. Positive for urine drug screening (morphine or marijuana);
  20. Subjects judged by the investigator as unsuitable for participating in this study.

    Additional exclusion criteria for subjects with hepatic insufficiency (those who meet any of the followings are ineligible):

  21. History of liver transplant;
  22. Liver failure, or liver cirrhosis complicated with hepatic encephalopathy, hepatocellular carcinoma, esophageal and gastric varices hemorrhage, and other complications that, in the opinion of the investigator, make subjects unsuitable for participating in this study;
  23. History of any serious diseases, other than primary liver diseases, or history of disorders and/or clinically significant abnormal laboratory findings that, as judged by the investigator, may affect the results of the study, including but not limited to the history of diseases in the circulatory system, endocrine system, nervous system, digestive system, urinary system or blood, immune, mental and metabolic diseases.
  24. Positive for HIV antibody screening; a rapid plasma reagin (RPR) test is required for a subject who tests positive for syphilis antibodies, and the subject should be excluded if the RPR result is also positive.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Mild hepatic impairment (Child-Pugh Class A)

    Drug: Hetrombopag Olamine Tablet

  • Experimental
    Moderate hepatic impairment (Child-Pugh Class B)

    Drug: Hetrombopag Olamine Tablet

  • Experimental
    Normal hepatic function

    Drug: Hetrombopag Olamine Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Peak plasma concentration (Cmax)

    Time frame: 0-120 hours post dose

  2. Area Under the plasma concentration vs time curve (AUC0-120).

    Time frame: 0-120 hours post dose

  3. Area under the blood concentration vs time curve (AUC0-inf).

    Time frame: 0-infinity

Secondary outcomes

  1. Time to Reach Maximum Drug Concentration in Plasma After Single Dose (Tmax)

    Time frame: 0-120 hours post dose

  2. Half-life Associated With the Terminal Slope (t½)

    Time frame: 0-120 hours post dose

  3. The number of volunteers with adverse events as a measure of safety and tolerability

    Time frame: up to Day 6

07

Study locations

1 site
  • The First Bethune Hospital of Jilin University
    Changchun, Jilin 130061, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Dec 2020, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2021
First posted
Oct 22, 2021
StartActual
Sep 28, 2020
Primary completionActual
Dec 4, 2020
CompletionActual
Dec 4, 2020
Last update
Oct 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05088642
Responsible party
Sponsor
First posted
Oct 22, 2021
Start date
Sep 28, 2020
Primary completion
Dec 4, 2020
Completion
Dec 4, 2020
Last update
Oct 22, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hetrombopag olamine

Start the discussion